Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Spataro

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Orphanet Journal of Rare Diseases|December 28, 2024
Two-year follow-up after drug desensitization in mucopolysaccharidosisFederico Spataro, Roberto Ria, Nada Chaoul, et al.
European Journal of Internal Medicine|June 19, 2026
Eosinophil-linked pulmonary circulation in EGPA Improves under anti-IL-5/R therapy: A longitudinal studyPalma Carlucci, Marialuisa Sveva Marozzi, Francesco Corvasce, et al.
Orphanet Journal of Rare Diseases|May 15, 2026
Combined omalizumab and desensitization to control IgE-mediated hypersensitivity in enzyme replacement therapy for late-onset Pompe diseaseAlberto Lerario, Elena Abati, Monica Sciacco, et al.
Allergy|June 25, 2025
Efficacy and Safety of Mepolizumab 300 mg in Eosinophilic Granulomatosis With Polyangiitis: A Meta-Analysis of Eight Retrospective StudiesFederico Spataro, Fabio Cacciapaglia, Palma Carlucci, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|April 3, 2023
Comparison of evidence of treatment effects in randomized and nonrandomized studies on allergen immunotherapyDanilo Di Bona, Palma Carlucci, Federico Spataro, et al.
Leukemia|February 17, 2026
Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysisFederico Spataro, Giuseppe Armentaro, Giuseppe Di Gioia, et al.
Orphanet Journal of Rare Diseases|November 4, 2022
Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)Federico Spataro, Fabio Viggiani, Domenico Giorgio Macchia, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Orphanet Journal of Rare Diseases|December 28, 2024
Two-year follow-up after drug desensitization in mucopolysaccharidosisFederico Spataro, Roberto Ria, Nada Chaoul, et al.
European Journal of Internal Medicine|June 19, 2026
Eosinophil-linked pulmonary circulation in EGPA Improves under anti-IL-5/R therapy: A longitudinal studyPalma Carlucci, Marialuisa Sveva Marozzi, Francesco Corvasce, et al.
Orphanet Journal of Rare Diseases|May 15, 2026
Combined omalizumab and desensitization to control IgE-mediated hypersensitivity in enzyme replacement therapy for late-onset Pompe diseaseAlberto Lerario, Elena Abati, Monica Sciacco, et al.
Allergy|June 25, 2025
Efficacy and Safety of Mepolizumab 300 mg in Eosinophilic Granulomatosis With Polyangiitis: A Meta-Analysis of Eight Retrospective StudiesFederico Spataro, Fabio Cacciapaglia, Palma Carlucci, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|April 3, 2023
Comparison of evidence of treatment effects in randomized and nonrandomized studies on allergen immunotherapyDanilo Di Bona, Palma Carlucci, Federico Spataro, et al.
Leukemia|February 17, 2026
Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysisFederico Spataro, Giuseppe Armentaro, Giuseppe Di Gioia, et al.
Orphanet Journal of Rare Diseases|November 4, 2022
Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)Federico Spataro, Fabio Viggiani, Domenico Giorgio Macchia, et al.
Pageof 3